Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2021 Financial and Operating Results Conference Call for February 28, 2022
February 22 2022 - 6:55AM
Business Wire
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
patient to pioneer a new era of Performance-Guided Surgery™,
announced today that it plans to release 2021 fourth quarter and
fiscal year 2021 financial and operating results after the market
closes on Monday, February 28, 2022. The Company will host a
conference call to discuss these results starting at 4:30 p.m. ET
the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial
1-855-327-6837 for domestic callers and 1-631-891-4304 for
international callers, and reference conference ID 10017809
approximately ten minutes prior to the start time. To access the
live audio webcast or archived recording, use the following link
https://ir.asensus.com/events-and-presentations. The replay will be
available on the Company’s website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220222005337/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer, 858-354-8850 CG Life kschaeffer@cglife.com
Asensus Surgical, Inc. (NYSE:ASXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Asensus Surgical, Inc. (NYSE:ASXC)
Historical Stock Chart
From Sep 2023 to Sep 2024